Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845416 · ClinicalTrials.gov registry record
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
A clinical trial of Severe Combined Immunodeficiency and T Cell Lymphocytopenia, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 1,800
- Enrollment target
- 2
- Study locations
NCT00845416 is a study of Severe Combined Immunodeficiency and T Cell Lymphocytopenia that has completed, run by University of California, San Francisco. The registered enrollment target is 1,800 participants, above the 38-participant average among 5 other Severe Combined Immunodeficiency trials with a reported enrollment target (4637% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT00845416, a study of Severe Combined Immunodeficiency and T Cell Lymphocytopenia, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 1,800 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the proposed research is to establish the validity of a newborn screening method for severe combined immunodeficiency (SCID). The assay to be used is developed on the basis of PCR quantification of T-cell receptor excision circles (TRECs) that is absent in SCID patients, thus correlating with the disease
Conditions Studied
Study Locations (2)
Arizona
- Chinle Hospital - Chinle
- Tuba City Hospital - Tuba City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845416
The ClinicalTrials.gov registry entry for NCT00845416 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 38-participant average among 5 other Severe Combined Immunodeficiency trials with a reported enrollment target (4637% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Severe Combined Immunodeficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00845416 reports 2 study locations spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT00845416 about?
NCT00845416 is a clinical study titled "Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population". The goal of the proposed research is to establish the validity of a newborn screening method for severe combined immunodeficiency (SCID). The assay to be used is developed on the basis of PCR quantification of T-cell receptor excision circles (TRECs) that is absent in SCID patients, thus correlating...
What is the current status of trial NCT00845416?
This trial is currently completed. The enrollment target is 1,800 participants. The study started on 2009-03. Estimated completion is 2011-11.
What conditions does trial NCT00845416 study?
This clinical trial studies the following conditions: Severe Combined Immunodeficiency, T Cell Lymphocytopenia.
Who is sponsoring clinical trial NCT00845416?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00845416 being conducted?
This trial has 2 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Combined Immunodeficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetic Basis of Immunodeficiency
RECRUITING
-
Autologous Gene Therapy for Artemis-Deficient SCID
RECRUITING · Phase 1
-
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
ACTIVE NOT RECRUITING · Phase 1
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
COMPLETED
-
IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.